News An aura of adult migraine hope as NICE recommends Vyepti Lundbeck’s eptinezumab receives NICE recommendation for the prevention of migraine in adults.
News Amid crowded migraine market, Lundbeck goes its own way The market for migraine treatment and prevention has been transformed by the launch of several new drugs targeting CGRP for many sufferers, but Lundbeck thinks there is still room for new a
News FDA approves 'potential blockbuster' migraine jab from Lundb... The FDA has approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs from a new class.
Oncology Takeda’s Innovent deal bears fruit, with Teresa Bitetti and ... Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
